TY - JOUR
T1 - Psychotropic drug use and alcohol drinking in community-dwelling older Australian men: The CHAMP study
AU - Ilomaki, Jenni
AU - Gnjidic, Danijela
AU - Hilmer, Sarah N
AU - Le Couteur, David
AU - Naganathan, Vasi
AU - Cummings, Robert
AU - Waite, Louise
AU - Seibel, Markus J
AU - Blyth, Fiona
AU - Handelsman, David J
AU - Bell, John Simon Frederick
PY - 2013
Y1 - 2013
N2 - Aim: To explore the association between psychotropic drug use and alcohol drinking in community-dwelling older Australian men. Design and Methods: We conducted a cross-sectional population-based study using baseline data collected between 2005 and 2007 from 1705 participants in the Concord Health and Ageing in Men Project (CHAMP) conducted in Sydney, Australia. All participants were men aged =70years. The prevalence of antidepressant and sedative or anxiolytic drug use was ascertained at clinical examinations and alcohol drinking was self-reported. Logistic regression models were used to compute the unadjusted and adjusted prevalence ratios and 95 confidence intervals for the association between sedative or anxiolytic use and antidepressant use with drinking patterns. Results: In the study sample, 8.0 used an antidepressant, 5.7 used a sedative or anxiolytic, 33.7 were daily drinkers, 13.9 were binge drinkers, 19.2 were heavy drinkers and 11.0 were problem drinkers. Overall, 27.1 of antidepressant users were daily drinkers and 42.7 of sedative or anxiolytic users were daily drinkers. Sedative or anxiolytic use was associated with daily drinking (prevalence ratio=1.42; 95 confidence intervals 1.09-1.76) but not with other drinking patterns. The associations between antidepressant use and alcohol drinking were not statistically significant. Discussion and Conclusions: Potential psychotropic drug-alcohol interactions were common in older Australian men. Users of sedative or anxiolytic drugs were more likely to engage in daily drinking compared with non-users of sedative or anxiolytic drugs. Clinicians should monitor patients prescribed sedative or anxiolytic drugs for possible adverse events arising from concomitant use with alcohol.
AB - Aim: To explore the association between psychotropic drug use and alcohol drinking in community-dwelling older Australian men. Design and Methods: We conducted a cross-sectional population-based study using baseline data collected between 2005 and 2007 from 1705 participants in the Concord Health and Ageing in Men Project (CHAMP) conducted in Sydney, Australia. All participants were men aged =70years. The prevalence of antidepressant and sedative or anxiolytic drug use was ascertained at clinical examinations and alcohol drinking was self-reported. Logistic regression models were used to compute the unadjusted and adjusted prevalence ratios and 95 confidence intervals for the association between sedative or anxiolytic use and antidepressant use with drinking patterns. Results: In the study sample, 8.0 used an antidepressant, 5.7 used a sedative or anxiolytic, 33.7 were daily drinkers, 13.9 were binge drinkers, 19.2 were heavy drinkers and 11.0 were problem drinkers. Overall, 27.1 of antidepressant users were daily drinkers and 42.7 of sedative or anxiolytic users were daily drinkers. Sedative or anxiolytic use was associated with daily drinking (prevalence ratio=1.42; 95 confidence intervals 1.09-1.76) but not with other drinking patterns. The associations between antidepressant use and alcohol drinking were not statistically significant. Discussion and Conclusions: Potential psychotropic drug-alcohol interactions were common in older Australian men. Users of sedative or anxiolytic drugs were more likely to engage in daily drinking compared with non-users of sedative or anxiolytic drugs. Clinicians should monitor patients prescribed sedative or anxiolytic drugs for possible adverse events arising from concomitant use with alcohol.
UR - http://onlinelibrary.wiley.com/doi/10.1111/j.1465-3362.2012.00496.x/pdf
U2 - 10.1111/j.1465-3362.2012.00496.x
DO - 10.1111/j.1465-3362.2012.00496.x
M3 - Article
VL - 32
SP - 218
EP - 222
JO - Drug and Alcohol Review
JF - Drug and Alcohol Review
SN - 0959-5236
IS - 2
ER -